BD Pen Needle

K162516 · Becton, Dickinson and Company · FMI · Dec 9, 2016 · General Hospital

Device Facts

• Record ID: K162516
• Device Name: BD Pen Needle
• Applicant: Becton, Dickinson and Company
• Product Code: FMI · General Hospital
• Decision Date: Dec 9, 2016
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 880.5570
• Device Class: Class 2
• Attributes: Therapeutic

Intended Use

BD Pen Needle is intended for use with pen injector devices for the subcutaneous injection of drugs.

Device Story

BD Pen Needle is a single-use, sterile, disposable hypodermic needle assembly consisting of a needle, hub, and shield. It attaches to pen injector devices for subcutaneous drug delivery. Operated manually by patients or healthcare providers in home or clinical settings. Device facilitates drug administration by providing a fluid path from the pen injector to the subcutaneous tissue. Benefits include reliable drug delivery and compatibility with leading diabetes pen injectors. No electronic or automated components; output is the physical delivery of the medication dose.

Clinical Evidence

Bench testing only. Validation performed per ISO 11608-2 requirements for needle-based injection systems. Internal quality system testing confirms compatibility with leading diabetes pen injectors to ensure connectivity and dose accuracy.

Technological Characteristics

Single-use, sterile, disposable needle assembly. Available in 29G, 30G, 31G, 32G gauges and 4mm, 5mm, 12.7mm lengths. Features 3 or 5 bevel tip geometry. Sterilized via gamma irradiation. Non-toxic and non-pyrogenic. Mechanical device; no software or energy source.

Indications for Use

Indicated for patients requiring subcutaneous drug delivery via pen injector devices. No specific age or gender restrictions; contraindicated only if patient has known hypersensitivity to device materials.

Regulatory Classification

Identification

A hypodermic single lumen needle is a device intended to inject fluids into, or withdraw fluids from, parts of the body below the surface of the skin. The device consists of a metal tube that is sharpened at one end and at the other end joined to a female connector (hub) designed to mate with a male connector (nozzle) of a piston syringe or an intravascular administration set.

Predicate Devices

• BD Pen Needle (K051899)
• BD Pen Needle (K131358)

Reference Devices

• BD AutoShield™ Duo Pen Needle (K110703)

Submission Summary (Full Text)

{0}------------------------------------------------

Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features the department's name arranged in a circular fashion around a symbol. The symbol consists of three stylized human profiles facing to the right, stacked on top of each other, with the top profile being the largest and the bottom profile being the the smallest.

Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002

December 9, 2016

Becton, Dickerson and Company Meriam Youssef Staff Regulatory Affairs Specialist 1 Becton Drive Franklin Lakes, New Jersey 07417

Re: K162516

Trade/Device Name: BD Pen Needle Regulation Number: 21 CFR 880.5570 Regulation Name: Hypodermic Single Lumen Needle Regulatory Class: II Product Code: FMI Dated: September 15, 2016 Received: September 16, 2016

Dear Meriam Youssef:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

{1}------------------------------------------------

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical devicerelated adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number [phone] or [phone] or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number [phone] or [phone] or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely,

Tina
Kiang-S

Tina Kiang, Ph.D. Acting Director Division of Anesthesiology. General Hospital, Respiratory, Infection Control, and Dental Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

# Indications for Use

510(k) Number (if known) K162516

Device Name BD Pen Needle

Indications for Use (Describe)

BD Pen Needle is intended for use with pen injector devices for the subcutaneous injection of drugs.

Type of Use (Select one or both, as applicable)

Prescription Use (Part 21 CFR 801 Subpart D)

|X | Over-The-Counter Use (21 CFR 801 Subpart C)

#### CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

#### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

> Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff [e-mail]

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{3}------------------------------------------------

# 510(k) Summary

| Submitted By: | Meriam Youssef<br>Staff Regulatory Affairs Specialist, BD Medical<br>1 Becton Drive<br>Franklin Lakes, NJ 07417<br>Tel: [phone]<br>Fax: [phone] | |
|----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------|
| Date Prepared: | December 7, 2016 | |
| Device Name: | Trade Name:<br>Common Name:<br>Classification:<br>Product Code: | BD Pen Needle<br>Insulin Pen Needle<br>Class II device; 21 CFR 880.5570,<br>(hypodermic single lumen needle)<br>FMI (hypodermic single lumen needle) |

### Legally marketed predicate devices to which substantial equivalence is being claimed:

K051899 and K131358: BD Pen Needle Reference Device: K110703: BD AutoShield™ Duo Pen Needle

#### Device Description:

The BD Pen Needle is designed for use with pen injectors for subcutaneous injection of a desired dose of drugs approved for delivery using a pen needle. It consists of a needle, hub, and shield assembly. The BD Pen Needle is offered in a variety of needle gauge sizes (29G, 30G, 31G, and 32G) and lengths (4mm, 5mm, and 12.7mm). It is a single-use disposable device that is provided sterile. The BD Pen Needle is non-toxic and nonpyrogenic.

#### Intended Use:

BD Pen Needle is intended for use with pen injector devices for the subcutaneous injection of drugs.

#### Comparison with Predicate Devices:

The subject device has the same device design, materials, fundamental scientific technology and device performance as the predicate devices (K051899 and K131358). The purpose of this submission is to provide clarification to the intended use which is similar amongst the cited predicate devices. The table below provides a side by side comparison of the subject device compared to its predicate.

{4}------------------------------------------------

| Feature | Subject: BD Pen Needle | Predicate Device: BD Pen Needle | Reference Device: BD<br>AutoShield™ Duo Pen<br>Needle |
|---------------------------------|--------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 510(k) Number | Pending | K051899 and K131358 | K110703 |
| Intended Use | Becton Dickinson Pen<br>Needle is intended for use<br>with pen injector devices<br>for the subcutaneous<br>injection of drugs. | Becton Dickinson Pen<br>Needle is intended for use<br>with pen injector devices<br>for the subcutaneous<br>injection of drugs,<br>including insulin and<br>exenatide. | For use with pen injector<br>devices for the injection of<br>drugs.<br>The product has two<br>safety shields, which lock<br>in place after use (patient-<br>end) and upon removal of<br>the needle from the pen<br>(pen connection-end).<br>The locked shields help<br>reduce the occurrence of<br>needle sticks from both<br>ends of the needle. |
| Needle Gauge Size(s) | Unchanged | 29G, 30G, 31G, 32G | 30G and 31G |
| Needle Length Size(s) | Unchanged | 4mm, 5mm,8mm, and<br>12.7mm | 5mm and 8mm |
| Tip Geometry<br>(Configuration) | Unchanged | 3 or 5 bevel | 3 bevel |
| Needle insertion method | Unchanged | Manual | Manual |
| Provided Sterile | Unchanged | YES (Gamma Irradiation) | YES (Gamma Irradiation) |

## Testing:

The subject device has the same technological characteristics as the predicate devices cleared in K051899 and K131358. BD has validated the design of the subject device as part of its design control process in accordance with the Ouality System Regulation. This testing included functional performance per ISO 11608-2: Needle-based injection systems for medical use -Requirements and test methods- Part 2: Needles.

The clarification to the intended use of the BD pen needle device, in the Instruction for Use, does not introduce critical differences or new risks to the intended therapeutic use of the device. The proposed clarification reflects current medical practice and aligns with BD's compatibility summary displayed on the device package. BD conducts internal testing as part of its Quality System, to support the compatibility of its pen needle devices with all leading diabetes pen injectors available on the market to ensure connectivity and dose accuracy. This testing demonstrates the BD Pen Needle device meet requirements for its intended use and supports the proposed clarification.

### Conclusion:

The subject device is substantially equivalent to its predicate devices.